Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.

Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, Montgomery RA, Ros RL, Segev DL.

Am J Transplant. 2011 Jun;11(6):1188-200. doi: 10.1111/j.1600-6143.2011.03460.x. Epub 2011 Mar 14. Review.

2.

Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysis.

Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, Montgomery RA, Ros RL, Segev DL.

Am J Transplant. 2011 Jun;11(6):1176-87. doi: 10.1111/j.1600-6143.2010.03329.x. Epub 2011 Mar 2. Review.

3.

Provider utilization of high-risk donor organs and nucleic acid testing: results of two national surveys.

Kucirka LM, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL.

Am J Transplant. 2009 May;9(5):1197-204. doi: 10.1111/j.1600-6143.2009.02593.x.

4.

A model to estimate the probability of human immunodeficiency virus and hepatitis C infection despite negative nucleic acid testing among increased-risk organ donors.

Annambhotla PD, Gurbaxani BM, Kuehnert MJ, Basavaraju SV.

Transpl Infect Dis. 2017 Apr;19(2). doi: 10.1111/tid.12676. Epub 2017 Mar 27.

PMID:
28178393
5.

Deceased organ donor screening for HIV, hepatitis B, and hepatitis C viruses: a survey of organ procurement organization practices.

Theodoropoulos N, Jaramillo A, Ladner DP, Ison MG.

Am J Transplant. 2013 Aug;13(8):2186-90. doi: 10.1111/ajt.12260. Epub 2013 May 24.

6.

Excerpt from PHS guideline for reducing HIV, HBV and HCV transmission through organ transplantation.

Seem DL, Lee I, Umscheid CA, Kuehnert MJ.

Am J Transplant. 2013 Aug;13(8):1953-62. doi: 10.1111/ajt.12386.

7.

Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios.

El Ekiaby M, Moftah F, Goubran H, van Drimmelen H, LaPerche S, Kleinman S, Busch M, Lelie N.

Transfusion. 2015 Jun;55(6):1186-94. doi: 10.1111/trf.13061. Epub 2015 Mar 13.

PMID:
25766141
8.

Transmission of Hepatitis C Virus From Organ Donors Despite Nucleic Acid Test Screening.

Suryaprasad A, Basavaraju SV, Hocevar SN, Theodoropoulos N, Zuckerman RA, Hayden T, Forbi JC, Pegues D, Levine M, Martin SI, Kuehnert MJ, Blumberg EA; Organ Transplantation Hepatitis C Investigation Team.

Am J Transplant. 2015 Jul;15(7):1827-35. doi: 10.1111/ajt.13283. Epub 2015 May 5.

9.

Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs.

Kucirka LM, Alexander C, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL.

Am J Transplant. 2009 Mar;9(3):620-8. doi: 10.1111/j.1600-6143.2008.02522.x. Epub 2009 Feb 3.

10.

Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis.

Lai JC, Kahn JG, Tavakol M, Peters MG, Roberts JP.

Am J Transplant. 2013 Oct;13(10):2611-8. doi: 10.1111/ajt.12429. Epub 2013 Aug 22.

11.
12.

Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.

Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ; German Red Cross NAT Study Group.

Transfusion. 2008 Aug;48(8):1558-66. doi: 10.1111/j.1537-2995.2008.01718.x. Epub 2008 May 6.

PMID:
18466173
13.

The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia.

Yao F, Seed C, Farrugia A, Morgan D, Cordner S, Wood D, Zheng MH.

Am J Transplant. 2007 Dec;7(12):2723-6.

14.

Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States.

Ellingson K, Seem D, Nowicki M, Strong DM, Kuehnert MJ; Organ Procurement Organization Nucleic Acid Testing Yield Project Team.

Am J Transplant. 2011 Jun;11(6):1201-8. doi: 10.1111/j.1600-6143.2011.03518.x.

15.

Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.

Bruhn R, Lelie N, Busch M, Kleinman S; International NAT Study Group.

Transfusion. 2015 Jun;55(6):1195-205. doi: 10.1111/trf.13024. Epub 2015 Feb 27.

PMID:
25727549
16.

Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing.

Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL.

Transfusion. 2010 Jul;50(7):1495-504. doi: 10.1111/j.1537-2995.2010.02622.x. Epub 2010 Mar 12.

PMID:
20345570
18.

Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.

Bird SM, Goldberg DJ, Hutchinson SJ.

J Epidemiol Biostat. 2001;6(3):243-65; discussion 279-85.

PMID:
11437088
19.

Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.

Weusten JJ, van Drimmelen HA, Lelie PN.

Transfusion. 2002 May;42(5):537-48.

PMID:
12084161
20.

Antibody to a hepatitis C virus related protein among patients at high risk for hepatitis B.

Widell A, Hansson BG, Berntorp E, Moestrup T, Johansson HP, Hansson H, Nordenfelt E.

Scand J Infect Dis. 1991;23(1):19-24.

PMID:
1851322

Supplemental Content

Support Center